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Background: The interplay between the main constituents of
cannabis, D9-tetrahydrocannabinol (THC) and cannabidiol (CBD),
has gained interest in recent years. THC has generally been
found to be anxiogenic, paranoia inducing, psychotogenic and
cognitively impairing, while CBD has demonstrated anxiolytic
and antipsychotic properties. There is evidence that THC and
CBD have opposite effects on brain function and that CBD may
ameliorate adverse effects of THC. The purpose of this study
was to examine the acute effects of each compound alone and
in combination on a candidate endophenotype for schizophrenia,
the mismatch negativity (MMN), which is reduced in amplitude
in patients and subserved by NMDA receptor function, to explore
mechanisms by which THC may trigger and CBD may ameliorate
psychotic-like brain phenomena.
Methods: In a double-blind placebo-controlled study, 36
healthy volunteers (31 male) comprising 18 experienced cannabis
users and 18 non-naı̈ve controls/irregular users (median lifetime
occasions of use 307 versus 24, respectively), underwent 5 ran-
domised drug sessions with a one week washout: 1. Placebo;
2. THC 8mg; 3. CBD 400mg; 4. CBD 4mg + THC 8mg
[LoCBD+THC]; 5. CBD 400mg + THC 12mg [HiCBD+THC].
Drugs were dissolved in 100% ethanol (which served as placebo)
and vaporised using a Volcano® Vaporiser. Participants com-
pleted a multifeature auditory oddball paradigm with duration
and frequency deviants (6% each). MMN amplitude was anal-
ysed at Fz. A 5 (drug condition) x 2 (MMN type) repeated
measures ANOVA with a between-subjects factor of group (users
vs. controls), was followed by planned comparisons to determine
(a) whether high dose CBD and THC alone affect MMN relative
to placebo; (b) whether low and high doses of CBD combined with
THC affect MMN relative to THC alone; and (c) whether effects
differ according to lifetime cannabis exposure.
Results: There was a significant drug by MMN type interaction
(F = 6.12, p< 0.001) and drug interacted with group (F = 2.89,
p< 0.025). CBD reduced while THC enhanced frequency MMN,
more so in users than controls, and CBD enhanced duration MMN
in controls but not users. Frequency MMN was more consistently
affected in the comparison of the three THC conditions, where a
significant drug by group interaction indicated that HiCBD+THC
significantly decreased frequency MMN amplitude relative to
THC alone and LoCBD+THC in users in particular, while trend
differences in controls indicated that LoCBD+THC tended to
reduce both frequency and duration MMN compared to THC.
Conclusions: While CBD may have opposite effects to THC
on frequency MMN, the pattern of results was less clear for
duration MMN, suggesting that these two components may be
subserved by differential underlying neurobiological interactions
with the endogenous cannabinoid system. The effects of CBD
were not typically in the direction expected with regard to potential
antipsychotic properties and when combined with THC differed
according to dose, prior exposure to cannabis and the nature of the
MMN investigated. Associations with psychotic-like symptoms,
cognitive function, endogenous cannabinoid levels and genotype
will be further explored.
